Edesa Biotech (EDSA) Competitors $2.46 -0.08 (-3.15%) Closing price 03:56 PM EasternExtended Trading$2.52 +0.06 (+2.64%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. STRO, PRLD, BYSI, ABVC, GANX, ARTV, TVRD, RLMD, DTIL, and INKTShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Sutro Biopharma (STRO), Prelude Therapeutics (PRLD), BeyondSpring (BYSI), ABVC BioPharma (ABVC), Gain Therapeutics (GANX), Artiva Biotherapeutics (ARTV), Tvardi Therapeutics (TVRD), Relmada Therapeutics (RLMD), Precision BioSciences (DTIL), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Its Competitors Sutro Biopharma Prelude Therapeutics BeyondSpring ABVC BioPharma Gain Therapeutics Artiva Biotherapeutics Tvardi Therapeutics Relmada Therapeutics Precision BioSciences MiNK Therapeutics Sutro Biopharma (NASDAQ:STRO) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk. Which has more volatility & risk, STRO or EDSA? Sutro Biopharma has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Is STRO or EDSA more profitable? Edesa Biotech has a net margin of 0.00% compared to Sutro Biopharma's net margin of -201.32%. Edesa Biotech's return on equity of -162.95% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Sutro Biopharma-201.32% -852.70% -58.67% Edesa Biotech N/A -162.95%-60.33% Does the media prefer STRO or EDSA? In the previous week, Sutro Biopharma had 4 more articles in the media than Edesa Biotech. MarketBeat recorded 5 mentions for Sutro Biopharma and 1 mentions for Edesa Biotech. Sutro Biopharma's average media sentiment score of 0.83 beat Edesa Biotech's score of 0.64 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Overall Sentiment Sutro Biopharma Positive Edesa Biotech Positive Do insiders and institutionals have more ownership in STRO or EDSA? 97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 3.6% of Sutro Biopharma shares are held by insiders. Comparatively, 22.6% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate STRO or EDSA? Sutro Biopharma presently has a consensus price target of $4.47, indicating a potential upside of 407.17%. Edesa Biotech has a consensus price target of $5.00, indicating a potential upside of 103.25%. Given Sutro Biopharma's higher possible upside, equities research analysts clearly believe Sutro Biopharma is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 2 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has higher earnings and valuation, STRO or EDSA? Edesa Biotech has lower revenue, but higher earnings than Sutro Biopharma. Edesa Biotech is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSutro Biopharma$104.47M0.71-$227.46M-$2.53-0.35Edesa BiotechN/AN/A-$6.17M-$1.32-1.86 SummarySutro Biopharma beats Edesa Biotech on 9 of the 16 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.31M$3.38B$6.13B$10.46BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-1.8623.0785.1527.20Price / SalesN/A446.16574.61178.68Price / CashN/A46.1137.3961.86Price / Book4.0310.5012.396.65Net Income-$6.17M-$52.47M$3.32B$276.79M7 Day Performance-5.75%-1.00%-0.24%-1.51%1 Month PerformanceN/A14.49%9.56%5.46%1 Year Performance-39.56%13.92%71.67%36.25% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech2.4263 of 5 stars$2.46-3.1%$5.00+103.3%-38.3%$17.31MN/A-1.8620News CoverageSTROSutro Biopharma4.1277 of 5 stars$0.82-0.9%$4.47+444.1%-79.6%$69.68M$62.04M-0.32240News CoverageGap UpPRLDPrelude Therapeutics3.4044 of 5 stars$1.23-1.9%$4.00+226.3%-28.8%$69.34M$7M-0.75120BYSIBeyondSpringN/A$1.70-0.6%N/A-33.7%$68.56M$1.75M0.0080News CoverageGap UpABVCABVC BioPharma0.6265 of 5 stars$2.91-1.9%N/A+394.0%$68.53M$510K-17.1230GANXGain Therapeutics3.0936 of 5 stars$1.93+1.3%$7.86+308.2%-22.1%$68.16M$50K-3.0120News CoverageAnalyst ForecastGap UpARTVArtiva Biotherapeutics3.378 of 5 stars$2.78+1.5%$17.00+511.5%-76.1%$67.92M$250K0.0081News CoverageTVRDTvardi Therapeutics2.5344 of 5 stars$6.99+4.5%$55.50+694.0%N/A$65.57M$7.14M0.0080Trending NewsAnalyst DowngradeAnalyst RevisionHigh Trading VolumeRLMDRelmada Therapeutics2.7699 of 5 stars$1.95-3.5%$1.00-48.7%-40.5%$64.72MN/A-0.8810DTILPrecision BioSciences3.8434 of 5 stars$5.44-2.2%$47.00+764.0%-26.1%$64.14M$68.70M-0.62200INKTMiNK Therapeutics2.6166 of 5 stars$14.02-0.5%$37.50+167.5%+122.3%$63.37MN/A-4.8730 Related Companies and Tools Related Companies STRO Competitors PRLD Competitors BYSI Competitors ABVC Competitors GANX Competitors ARTV Competitors TVRD Competitors RLMD Competitors DTIL Competitors INKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
